ATP2C2 and chronic obstructive pulmonary disease: In contrast, only 6.9% of individuals harboring multiple pLoF + damaging missense/protein-altering variants on the same ATP2C2 haplotype were diagnosed with COPD, with the same median age of diagnosis (60.8 [53.7–67.9] years) as both heterozygote carriers (58.0 [48.5–64.1] years) and those with wild type (59.2 [51.3–65.1] years).